Literature DB >> 11053981

Low leptin mRNA level in adipose tissue and normoleptinemia in experimental chronic renal failure.

J Swierczynski1, J Korczynska, M Szolkiewicz, J Karbowska, Z Kochan, T Nieweglowski, E Kusiak, B Rutkowski.   

Abstract

BACKGROUND: Anorexia and weight loss frequently accompany chronic renal failure (CRF). Although multiple metabolic changes occur during CRF, a bulk of evidence indicates that the decrease in caloric intake plays a major role in CRF-induced weight loss. Recently, it has been suggested that elevated plasma leptin concentrations could contribute to anorexia and to downregulation of leptin gene expression in CRF patients. However, in some CRF patients, plasma leptin concentrations have been found to be lower than one could expect. Thus we assumed that inhibition of leptin synthesis plays an important role in the regulation of plasma leptin concentrations in CRF patients.
METHODS: To test this assumption, the leptin mRNA level in rat white adipose tissue from ad-libitum-fed control (sham operated), pair-fed control (sham operated) and rats with experimentally induced CRF has been measured by Northern blotting analysis. In addition, serum leptin concentration (by radioimmunoassay) was determined in all three groups of animals.
RESULTS: The results of the present study indicate that in experimental CRF the leptin mRNA level is decreased by about 50% as compared to the sham-operated animals (ad-libitum-fed and pair-fed controls). The mean serum leptin concentration in CRF rats was essentially similar to the leptin concentration in sham-operated ones.
CONCLUSION: The data obtained suggest that in CRF animals the serum leptin concentration might be affected not only by the decrease in leptin removal in the kidney, but also by the decrease in leptin secretion from adipose tissue. Furthermore, the results of the study suggest that leptin may be only one of many factors involved in the pathogenesis of malnutrition associated with CRF. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11053981     DOI: 10.1159/000020699

Source DB:  PubMed          Journal:  Exp Nephrol        ISSN: 1018-7782


  6 in total

1.  Diurnal rhythm of cholesterol biosynthesis in experimental chronic renal failure.

Authors:  M Chmielewski; T Nieweglowski; J Swierczynski; B Rutkowski; W Boguslawski
Journal:  Mol Cell Biochem       Date:  2001-12       Impact factor: 3.396

2.  Contribution of increased HMG-CoA reductase gene expression to hypercholesterolemia in experimental chronic renal failure.

Authors:  Michal Chmielewski; Elzbieta Sucajtys; Julian Swierczynski; Boleslaw Rutkowski; Wojciech Bogusławski
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

3.  Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure.

Authors:  Elzbieta Sucajtys-Szulc; Marek Szolkiewicz; Julian Swierczynski; Boleslaw Rutkowski
Journal:  Mol Cell Biochem       Date:  2015-10-19       Impact factor: 3.396

Review 4.  The Causes and Potential Injurious Effects of Elevated Serum Leptin Levels in Chronic Kidney Disease Patients.

Authors:  Justyna Korczynska; Aleksandra Czumaj; Michal Chmielewski; Julian Swierczynski; Tomasz Sledzinski
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

5.  Hepatocyte Nuclear Factor 1α Proinflammatory Effect Linked to the Overexpression of Liver Nuclear Factor-κB in Experimental Model of Chronic Kidney Disease.

Authors:  Elzbieta Sucajtys-Szulc; Alicja Debska-Slizien; Boleslaw Rutkowski; Marek Szolkiewicz; Julian Swierczynski; Ryszard Tomasz Smolenski
Journal:  Int J Mol Sci       Date:  2022-08-10       Impact factor: 6.208

6.  Hepatocyte nuclear factors as possible C-reactive protein transcriptional inducer in the liver and white adipose tissue of rats with experimental chronic renal failure.

Authors:  Elzbieta Sucajtys-Szulc; Alicja Debska-Slizien; Boleslaw Rutkowski; Ryszard Milczarek; Iwona Pelikant-Malecka; Tomasz Sledzinski; Julian Swierczynski; Marek Szolkiewicz
Journal:  Mol Cell Biochem       Date:  2018-01-12       Impact factor: 3.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.